PapersFlow Research Brief

Health Sciences · Medicine

Venous Thromboembolism Diagnosis and Management
Research Guide

What is Venous Thromboembolism Diagnosis and Management?

Venous Thromboembolism Diagnosis and Management is the clinical process of preventing, diagnosing, and treating venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, through antithrombotic therapies, risk assessment, prophylaxis, and adherence to evidence-based guidelines.

The field includes 162,835 published works on VTE prevention, diagnosis, and treatment. Key areas cover antithrombotic therapy, risk factors, prophylaxis, and management in cancer patients. Clinical practice guidelines direct the use of tools like Wells' Criteria for pretest probability assessment.

Topic Hierarchy

100%
graph TD D["Health Sciences"] F["Medicine"] S["Internal Medicine"] T["Venous Thromboembolism Diagnosis and Management"] D --> F F --> S S --> T style T fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan
162.8K
Papers
N/A
5yr Growth
2.0M
Total Citations

Research Sub-Topics

Why It Matters

Venous thromboembolism diagnosis and management reduces mortality and morbidity from deep vein thrombosis and pulmonary embolism, the third most common fatal cardiovascular condition in the United States. Kearon et al. (2012) in "Antithrombotic Therapy for VTE Disease" outline therapies that balance efficacy against bleeding risks, guiding treatment in diverse populations including cancer patients. Geerts et al. (2004) in "Prevention of Venous Thromboembolism" demonstrate prophylaxis reduces VTE incidence postoperatively, with specific recommendations for orthopedic surgery yielding complication reductions. Recent guidelines like the 2025 ESC on acute VTE management in pregnancy and ESVM guidelines on interventional treatments expand options for high-risk groups.

Reading Guide

Where to Start

"Antithrombotic Therapy for VTE Disease" by Kearon et al. (2012), as it provides a foundational overview of treatment strategies directly addressing VTE management with 6102 citations.

Key Papers Explained

Kearon et al. (2012) in "Antithrombotic Therapy for VTE Disease" establishes core treatment principles, complemented by Geerts et al. (2004) in "Prevention of Venous Thromboembolism" focusing on prophylaxis strategies with 5875 citations. Lip et al. (2009) in "Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach" refines risk assessment applicable to VTE contexts (6570 citations). Patel et al. (2011) in "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation" introduces direct oral anticoagulant evidence (9227 citations), building toward guideline integration.

Paper Timeline

100%
graph LR P0["A randomised, blinded, trial of ...
1996 · 6.5K cites"] P1["Collaborative meta-analysis of r...
2002 · 6.9K cites"] P2["Correspondence - Tranexamic acid...
2005 · 11.7K cites"] P3["Prasugrel versus Clopidogrel in ...
2007 · 6.7K cites"] P4["Refining Clinical Risk Stratific...
2009 · 6.6K cites"] P5["Rivaroxaban versus Warfarin in N...
2011 · 9.2K cites"] P6["Endovascular thrombectomy after ...
2016 · 7.2K cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P2 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Recent preprints highlight 2025 ESC Guidelines for acute VTE management in pregnancy by Hobohm et al., ESVM Guidelines on interventional VTE treatments, and protocols for real-time VTE prediction models in hospitalized patients. Meta-analyses on central venous catheter complications inform prophylaxis refinements. AAFP updates emphasize Wells' Criteria in diagnosis.

Papers at a Glance

In the News

Code & Tools

Recent Preprints

Latest Developments

Recent developments in venous thromboembolism (VTE) research as of February 2026 include advances in diagnosis, management, and interventional treatments, with ongoing updates from major symposiums such as the Johns Hopkins VTE Symposium scheduled for March 2026 (MDPI; Johns Hopkins; pubmed). Key areas of progress involve new anticoagulant drugs, minimally invasive thrombectomy devices, improved imaging technologies, and validated risk assessment models, with recent guidelines emphasizing efficient diagnostic strategies (MDPI; ASH; JAMA).

Frequently Asked Questions

What are the main components of antithrombotic therapy for VTE?

Antithrombotic therapy for VTE disease involves anticoagulants selected based on patient risk and bleeding profile. Kearon et al. (2012) in "Antithrombotic Therapy for VTE Disease" recommend initial parenteral therapy followed by oral agents for acute and extended treatment. Therapy duration varies from 3 months to indefinite based on recurrence risk.

How is VTE risk stratified in clinical practice?

VTE risk stratification uses clinical prediction rules like Wells' Criteria for DVT and PE to determine pretest probability. These tools guide diagnostic imaging decisions. Low-probability patients may avoid immediate testing, reducing unnecessary procedures.

What prophylaxis strategies prevent VTE?

Prophylaxis strategies include pharmacologic agents like low-molecular-weight heparin and mechanical methods. Geerts et al. (2004) in "Prevention of Venous Thromboembolism" provide recommendations for surgical patients, showing reduced VTE events with tailored regimens. Cancer patients require extended prophylaxis per guidelines.

What role do direct oral anticoagulants play in VTE management?

Direct oral anticoagulants like rivaroxaban offer noninferior efficacy to warfarin for VTE-related stroke prevention. Patel et al. (2011) in "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation" report lower intracranial bleeding rates with rivaroxaban. These agents simplify outpatient management.

How are VTE guidelines applied in special populations like cancer patients?

Cancer-associated thrombosis management favors low-molecular-weight heparin over vitamin K antagonists initially. Guidelines emphasize prolonged prophylaxis due to elevated recurrence risks. Recent ACE Clinical Guidelines specify anticoagulant selection for cancer patients with VTE.

Open Research Questions

  • ? How can real-time prognostic models improve VTE prediction accuracy in hospitalized adults?
  • ? What are the optimal durations and agents for anticoagulation in cancer-associated VTE?
  • ? Which endovascular interventions yield the best outcomes for acute VTE compared to systemic therapies?
  • ? How do central venous catheter complication rates influence prophylaxis protocols?
  • ? What refinements to Wells' Criteria enhance diagnostic precision for diverse populations?

Research Venous Thromboembolism Diagnosis and Management with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Venous Thromboembolism Diagnosis and Management with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers